Severe Combined Immunodeficiency (SCID) and Its New Treatment Modalities

Akshad M Wadbudhe1, Revat J Meshram1, Shivangi C Tidke1

  • 1Department of Paediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.

Cureus
|November 29, 2023
PubMed

Insights

Severe combined immunodeficiency (SCID) is a rare genetic disorder impairing the immune system, leading to severe infections. Early diagnosis and advanced treatments like gene therapy offer improved survival rates for affected infants.

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Severe combined immunodeficiency (SCID) is a rare, life-threatening genetic disorder characterized by a severely impaired immune system.
  • Caused by genetic mutations, SCID leaves infants vulnerable to opportunistic infections, often presenting with symptoms like respiratory and meningeal infections.
  • Historically known as "bubble boy disease," SCID requires prompt medical intervention due to high mortality rates.

Purpose of the Study:

  • To provide a comprehensive overview of severe combined immunodeficiency (SCID).
  • To discuss the challenges in diagnosing SCID due to its genetic complexity.
  • To review the latest advancements in SCID treatment modalities.

Main Methods:

  • This is a narrative review article.
  • Information was gathered from existing literature on SCID.
  • Focus is on describing the condition and its evolving treatments.

Main Results:

  • SCID diagnosis has improved significantly due to advanced newborn screening, enabling detection within three months of age.
  • Despite genetic complexity complicating diagnosis, newer monitoring systems enhance early identification.
  • Mortality rates have decreased with earlier diagnosis and improved treatment options.

Conclusions:

  • Early diagnosis of SCID is crucial for improving infant survival rates.
  • Hematopoietic stem cell transplantation, gene therapy, enzyme replacement therapy, and chemotherapy are key treatment strategies.
  • Continued research and advancements in screening and treatment are vital for managing SCID effectively.

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
947
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
244
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
68.4K